Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study

Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study AbstractBACKGROUNDStereotactic radiosurgery (SRS) is a treatment option for persistent or recurrent acromegaly secondary to a growth hormone secreting pituitary adenoma, but its efficacy is inadequately defined.OBJECTIVETo assess, in a multicenter, retrospective cohort study, the outcomes of SRS for acromegaly and determine predictors.METHODSWe pooled and analyzed data from 10 participating institutions of the International Gamma Knife Research Foundation for patients with acromegaly who underwent SRS with endocrine follow-up of ≥6 mo.RESULTSThe study cohort comprised 371 patients with a mean endocrine follow-up of 79 mo. IGF-1 lowering medications were held in 56% of patients who were on pre-SRS medical therapy. The mean SRS treatment volume and margin dose were 3.0 cm3 and 24.2 Gy, respectively. The actuarial rates of initial and durable endocrine remission at 10 yr were 69% and 59%, respectively. The mean time to durable remission after SRS was 38 mo. Biochemical relapse after initial remission occurred in 9%, with a mean time to recurrence of 17 mo. Cessation of IGF-1 lowering medication prior to SRS was the only independent predictor of durable remission (P = .01). Adverse radiation effects included the development of ≥1 new endocrinopathy in 26% and ≥1 cranial neuropathy in 4%.CONCLUSIONSRS is a definitive treatment option for patients with persistent or recurrent acromegaly after surgical resection. There appears to be a statistical association between the cessation of IGF-1 lowering medications prior to SRS and durable remission. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study

Download PDF
9 pages

Loading next page...
 
/lp/ou_press/stereotactic-radiosurgery-for-acromegaly-an-international-multicenter-Op1DNwSqQf
Publisher
Oxford University Press
Copyright
Copyright © 2018 by the Congress of Neurological Surgeons
ISSN
0148-396X
eISSN
1524-4040
DOI
10.1093/neuros/nyy178
Publisher site
See Article on Publisher Site

Abstract

AbstractBACKGROUNDStereotactic radiosurgery (SRS) is a treatment option for persistent or recurrent acromegaly secondary to a growth hormone secreting pituitary adenoma, but its efficacy is inadequately defined.OBJECTIVETo assess, in a multicenter, retrospective cohort study, the outcomes of SRS for acromegaly and determine predictors.METHODSWe pooled and analyzed data from 10 participating institutions of the International Gamma Knife Research Foundation for patients with acromegaly who underwent SRS with endocrine follow-up of ≥6 mo.RESULTSThe study cohort comprised 371 patients with a mean endocrine follow-up of 79 mo. IGF-1 lowering medications were held in 56% of patients who were on pre-SRS medical therapy. The mean SRS treatment volume and margin dose were 3.0 cm3 and 24.2 Gy, respectively. The actuarial rates of initial and durable endocrine remission at 10 yr were 69% and 59%, respectively. The mean time to durable remission after SRS was 38 mo. Biochemical relapse after initial remission occurred in 9%, with a mean time to recurrence of 17 mo. Cessation of IGF-1 lowering medication prior to SRS was the only independent predictor of durable remission (P = .01). Adverse radiation effects included the development of ≥1 new endocrinopathy in 26% and ≥1 cranial neuropathy in 4%.CONCLUSIONSRS is a definitive treatment option for patients with persistent or recurrent acromegaly after surgical resection. There appears to be a statistical association between the cessation of IGF-1 lowering medications prior to SRS and durable remission.

Journal

Neurosurgery – Oxford University Press

Published: Mar 1, 2019

References

  • Acromegaly
  • American Association of Clinical Endocrinologists Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update
  • Management of hormone-secreting pituitary adenomas
  • A consensus on criteria for cure of acromegaly
  • Endoscopic endonasal versus microsurgical transsphenoidal approach for growth hormone-secreting pituitary adenomas-systematic review and meta-analysis
  • Acromegaly: an endocrine society clinical practice guideline
  • Stereotactic radiosurgery for acromegaly
  • Radiation therapy in the management of pituitary adenomas
  • Results of gamma knife radiosurgery in acromegaly
  • Gamma knife radiosurgery for clinically persistent acromegaly
  • The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma
  • Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion
  • Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy
  • Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy
  • Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes
  • Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error
  • Octreotide may act as a radioprotective agent in acromegaly
  • Hypopituitarism after stereotactic radiosurgery for pituitary adenomas
  • Whole-sellar stereotactic radiosurgery for functioning pituitary adenomas
  • Multisession gamma knife radiosurgery: a preliminary experience with a noninvasive, relocatable frame
  • Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity
  • Cranial nerve dysfunction following Gamma Knife surgery for pituitary adenomas: long-term incidence and risk factors
  • Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission
  • Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis
  • Clinical and economic burden of commercially insured patients with acromegaly in the united states: a retrospective analysis
  • Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases
  • Inception of a national multidisciplinary registry for stereotactic radiosurgery
  • Increased Risk of Persistent Glucose Disorders After Control of Acromegaly
  • Long-term results of stereotactic radiosurgery in secretory pituitary adenomas
  • Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study
  • Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission
  • Octreotide may act as a radioprotective agent in acromegaly